Science

Neuroprotection is the priority

The problem:

The main treatments for GLAUCOMA currently in development are aimed at reducing or controlling intraocular pressure (IOP), but they are not neuroprotective, meaning they do not cure the disease. This means that the disease continues to progress, reducing the visual field and worsening patients’ vision and quality of life. In addition, with current drugs, more than 40% of cases show no response, and 10% of patients progress to complete blindness within 7 to 15 years. The current pharmaceutical market for glaucoma treatments focuses on lowering IOP, but it does not offer alternatives.

NEUROPROTECTION is a fundamental priority to prevent blindness from glaucoma and the loss of visual field as the disease progresses.

 

Eye

Solution:

Our competitive advantage is a drug called CILASTATIN, developed and patented by the Telara Pharma team. CILASTATIN has shown unprecedented NEUROPROTECTION of the retina, preventing damage to retinal ganglion cells without reducing IOP, representing a disruptive treatment for glaucoma and other neurodegenerative ocular diseases.

See pipeline
Telara

Target Market:

Currently, more than 60 million people worldwide have GLAUCOMA, and this number continues to rise due to population aging. The total number of prevalent glaucoma cases worldwide is expected to reach 112 million by 2040 (>1% of the global population). GLAUCOMA is the leading cause of blindness in people over 60 years of age.

However, in most cases, even when treated with the drugs currently available to reduce intraocular pressure, the disease continues to progress and damage the retina and the optic nerve.